{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-113299","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.997803+00:00","generated_at":"2026-05-22T13:45:33.541732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors","bullets":["Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.","Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.","Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.","Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-113299","json":"https://secwatch.observer/filing/0001193125-25-113299.json","markdown":"https://secwatch.observer/filing/0001193125-25-113299.md","text":"https://secwatch.observer/filing/0001193125-25-113299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/0001193125-25-113299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/d923057d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T13:45:33.541732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}